Arcutis Biotherapeutics, Inc. on March 5, 2026 announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company?s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE (roflumilast) portfolio, and protection of the Company?s intellectual property, as well as any corporate transactions. Mr. Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary, leading legal and compliance strategy and serving as secretary to the Board of Directors.
He has helped guide the Company through a period of significant commercial growth, including six FDA approvals of the Company?s advanced targeted topical, ZORYVE, while building and scaling the Company?s legal, compliance, and governance framework. Prior to Arcutis, Mr. Matsuda served as senior vice president, general counsel, chief compliance officer, and corporate secretary at Halozyme Therapeutics, Inc. and previously held numerous legal positions including vice president, law, global commercial operations at Amgen.
